Royalty Pharma plc

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Royalty Pharma plc trades at $57.5, in a confirmed uptrend and 71 weeks into that stage. That is +23.2% against its own 200-day average. It sits at 94% of a 52-week range of $35 to $59. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 39 straight weeks.

Today the stock is in a confirmed uptrend — week 71 of stage 2. At $57.5 it trades +23.2% versus its 200-day average and sits at 94% of its 52-week range ($35–$59).

Against the market, two honest reads. Cumulative: over the last 6.1 years the stock moved +17% while the S&P 500 moved +150% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 39 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

Royalty Pharma plc trades at 30.2× P/E, mid-range by its own standards (63rd percentile). Its long-run median P/E is 25.4×, measured across 4.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 30.2× is mid-range by its own standards (63rd percentile), against a long-run median of 25.4× measured over 4.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

🚨 Why the multiple sits where it does: over the past year annual EPS moved −6.8% against a +54.9% price move — the price outran earnings, pushing the multiple UP its own range.

The price move, decomposed: over 3y, of the +23.4%/yr price move, ~+52.4%/yr came from earnings growth and ~−29.0 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Royalty Pharma plc reads as deteriorating on its fundamental arc. Deteriorating — profit and EPS growth are shrinking (profit growth −22.7% latest against +639.1% at its 12-quarter best), ROCE holding at 8.9%. The read is built from 12 quarters across 4 curves, on full evidence.

🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.

4-Factor Sector Score

55.4/100 — rank 9 of 30 in Biotechnology · 81% evidence confidence

Royalty Pharma plc scores 55.4 out of 100 against the 30 companies it is compared with in Biotechnology, ranking 9. Price leads the evidence: RS versus the benchmark is 15.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation.

The four contributions add to the total exactly: 12.1 + 13.5 + 14.3 + 15.5 = 55.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Royalty Pharma plc reported $0.6 B of revenue in the Mar 26 quarter, +10.5% year on year. That is the 4th straight quarter of year-on-year growth. Over 4 years it has compounded at 1.0% a year. The last full year, FY25, came in at $2.4 B. The last four reported quarters add to $2.4 B.

FY25 revenue came in at $2.4 B (+5.3% on the year), capping 4 years at 1.0% compound. The latest quarter (Mar 26) printed $0.6 B, +10.5% year on year — the 4th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +8.0% growth against the decade's 1.0% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +8.0% over the last 4 quarters against +4.1%/yr over the last 8 — accelerating; TTM profit −22.7% vs +6.9%/yr — rolling over.

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Royalty Pharma plc's operating margin is 88.9% in the Mar 26 quarter, −4.1 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged 13.8% to 65.5%. The current quarter is running above every full year in that window.

The latest quarter's operating margin is 88.9%, −4.1 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 13.8%–65.5%, and FY25's 65.5% is the top of that band — a record year.

🚨 Why the margin moved: operating margin went −4.1 pp year on year while gross margin went +8.9 pp — the loss came mostly from the gross line: input costs and pricing.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Royalty Pharma plc earned $0.5 B of net profit in the Mar 26 quarter, +9.3% year on year. It is the 2nd consecutive quarter of growth. Full-year FY25 profit was $1.3 B. The 4-year compound rate is 1.6%. That is 74.6% of the quarter's revenue. The same quarter a year earlier earned $0.4 B.

Mar 26 profit was $0.5 B, +9.3% year on year — the 2nd consecutive quarter of growth. On the full year, FY25 printed $1.3 B (−0.8%), and the 4-year compound rate is 1.6%.

Why profit moved: revenue contributed +10.5% and the margin −4.1 pp — the quarter was revenue-led despite a thinner margin.

Pace comparison, last four quarters: profit −20.0% vs revenue +8.0%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 190% of Royalty Pharma plc's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $2.5 B of operating cash against $1.3 B of profit. After null of capital spending, $2.5 B was left as free cash.

FY25: operating cash of $2.5 B against reported profit of $1.3 B, leaving free cash of $2.5 B after null of capital spending. Across the last 3 fiscal years the conversion rate is 190% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.

Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Royalty Pharma plc does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Nothing is estimated in place of the missing day-counts, so no cash-cycle chart is drawn.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

Royalty Pharma plc earns a ROE of 14% in FY25. That is up from a trough of 2% in FY22. Return on invested capital clears the cost of that capital by −0.1 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 55.5% net margin on 0.12× asset turns.

FY25 ROE is 14%, recovered from a FY22 trough of 2% — the full ladder below shows the fall and the climb, undoctored.

🚨 Why the return is what it is — the wiring (FY25): 55.5% net margin × 0.12× asset turns × 2.02× balance-sheet leverage ≈ 13.5% on equity. Margin is doing the heavy lifting; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 5.7% − 5.8% = a −0.1 pp spread. The 5.8% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.

Royalty Pharma plc paid $0.90 per share over the last four reported quarters, up 6.8% on a year ago. The most recent declaration was $0.23 for Mar 26. Against the current price of $57.5 that is a trailing yield of 1.57%, measured on dividends already paid rather than on a forecast.

Royalty Pharma plc paid $0.90 per share across the last four reported quarters, most recently $0.23 for Mar 26. That is up 6.8% against the same quarter a year earlier. Against the current price of $57.5 the trailing twelve months work out to 1.57% — trailing dividends measured against today's price, not a forward estimate.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Royalty Pharma plc carries total debt of $9.0 B against shareholder equity of $9.9 B as of Mar 26, a debt-to-equity of 0.90. On the annual view that ratio went from 0.69 in FY21 to 0.92 in FY25. Read the returns elsewhere on this page with that leverage in mind.

Mar 26: total debt of $9.0 B against shareholder equity of $9.9 B — a debt-to-equity of 0.90. On the annual view, debt-to-equity went from 0.69 (FY21) to 0.92 (FY25). Read the returns on this page with that leverage in mind.

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

2.9% of Royalty Pharma plc's tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 3.5 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 2.9% of the float is sold short, and at typical trading volumes it would take about 3.5 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Royalty Pharma plc: the Z-score reads 1.61. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits inside the distress zone. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

🚨 Why it matters: a Z-score of 1.61 is inside the distress zone — the balance sheet is a real risk, not a detail.

The safety line in one sentence: the Z-score reads 1.61.

Frequently asked questions